General Pharmacology Practice Questions

Q: What is the classification of Lorcaserin?

Anti-obesity. ***Anti-obesity*** - Lorcaserin is a selective **serotonin 5-HT₂C receptor agonist** that works by promoting satiety and reducing food intake. - It is prescribed as a long-term treatment for **weight management** in adults who are obese or overweight with at least one weight-related comorbidity. *Anti-anxiety* - Anti-anxiety medications, such as **benzodiazepines** or **SSRIs**, primarily target neurotransmitters like GABA or serotonin 5-HT₁A receptors to reduce anxiety symptoms. - Lorcaserin's primary mechanism of action is distinct, focusing on the 5-HT₂C receptor for appetite regulation, not anxiety. *Anti-smoking* - Anti-smoking medications, like **varenicline** or **bupropion**, are designed to reduce nicotine cravings and withdrawal symptoms. - Their mechanisms often involve nicotinic acetylcholine receptors or dopamine and norepinephrine reuptake inhibition, which differs from lorcaserin's action. *Anti-helminthic* - Anti-helminthic drugs are used to treat **parasitic worm infections** by paralyzing or killing the worms. - Common examples include **albendazole** or **mebendazole**, which have no relation to appetite control or obesity treatment.

Q: Which of the following pairs are considered physiological antagonists in pharmacology?

Histamine and Adrenaline. ***Histamine and Adrenaline*** - **Physiological antagonism** occurs when two drugs produce opposite effects by acting on different receptors or pathways. - **Histamine** causes bronchoconstriction and vasodilation, while **adrenaline** causes bronchodilation and vasoconstriction, counteracting each other's effects through different mechanisms. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **adrenergic agonists** that produce similar physiological effects, primarily through beta-adrenergic receptor activation. - They are not physiological antagonists but rather have **synergistic** or similar pharmacological actions. *Isoprenaline and Propranolol* - **Isoprenaline** is a **beta-adrenergic agonist**, while **propranolol** is a **beta-adrenergic antagonist**. - This is an example of **pharmacological antagonism (receptor antagonism)**, where one drug blocks the effect of another at the same receptor site, rather than physiological antagonism.

Q: The mechanism by which ergometrine stops postpartum hemorrhage is that it:

Increases tone of uterine muscle. ***Increases tone of uterine muscle*** - **Ergometrine** is an **ergot alkaloid** that directly stimulates **uterine smooth muscle contractions**. - These sustained contractions lead to **compression of blood vessels within the myometrium**, thereby reducing blood flow and controlling **postpartum hemorrhage**. *Causes vasoconstriction of uterine arteries* - While ergometrine does have some generalized **vasoconstrictive effects**, its primary mechanism of action in controlling postpartum hemorrhage is not mainly through direct vasoconstriction of large uterine arteries. - The crucial effect is the **sustained uterine contraction** which mechanically occludes blood vessels, rather than chemical constriction of the vessels themselves. *Induces platelet aggregation* - Ergometrine does not primarily act by inducing **platelet aggregation**; this is a function of specific clotting factors and platelet activators. - Its therapeutic effect against hemorrhage is mediated through its action on **uterine contractility**, not on the cellular components of coagulation. *Promotes coagulation* - Ergometrine does not directly promote the **coagulation cascade** or enhance the formation of fibrin clots. - Its mechanism of action is distinct from agents that affect intrinsic or extrinsic pathways of coagulation.

Q: In ophthalmology, if a patient is allergic to aminoesters, which local anesthetic can be safely used?

Prilocaine. **Local anesthetics are classified into two chemical groups: esters (aminoesters) and amides. Allergies to esters typically do not cross-react with amides.** ***Prilocaine*** - **Prilocaine** is an **amide-type local anesthetic**, and allergies to **aminoesters** typically do not cross-react with **amides**. - It is a safe alternative in patients with a known allergy to **ester-type local anesthetics**. *Cocaine* - **Cocaine** is an **ester-type local anesthetic**, sharing a similar chemical structure with **aminoesters**. - Patients allergic to **aminoesters** are likely to experience a **cross-reaction** with **cocaine**. *Procaine* - **Procaine** is a classic **ester-type local anesthetic** (an aminoester). - An allergy to aminoesters directly implies an allergy to **procaine** due to its chemical classification. *Tetracaine* - **Tetracaine** is also an **ester-type local anesthetic** (an aminoester). - It is contraindicated in patients with an allergy to **aminoesters** due to the high risk of **allergic reaction**.

Q: Which drug is used in the treatment of Type I tyrosinemia?

Nitisinone. ***Nitisinone*** - **Nitisinone** (brand name Orfadin) is specifically approved for the treatment of **hereditary tyrosinemia type 1 (HT-1)**. - It works by inhibiting 4-hydroxyphenylpyruvate dioxygenase, an enzyme upstream of the deficient enzyme in HT-1, thereby reducing the production of toxic metabolites. *Alogliptin* - **Alogliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of **Type 2 diabetes mellitus**. - It helps to lower blood glucose levels by increasing the half-life of **incretin hormones**, which stimulate insulin release. *Pemoline* - **Pemoline** is a central nervous system (CNS) stimulant that was formerly used to treat **attention deficit hyperactivity disorder (ADHD)** and narcolepsy. - Its use has been largely discontinued due to concerns about its potential for **liver toxicity**. *Milrinone* - **Milrinone** is a phosphodiesterase-3 inhibitor used in the short-term management of **decompensated heart failure**. - It increases **cardiac contractility** and causes vasodilation, improving cardiac output.

Q: Ranibizumab is a monoclonal antibody against?

VEGF. ***VEGF*** - **Ranibizumab** is a **monoclonal antibody** specifically designed to inhibit **vascular endothelial growth factor A (VEGF-A)**. - By binding to VEGF-A, ranibizumab prevents its interaction with receptors on endothelial cells, thereby inhibiting **angiogenesis** and reducing vascular permeability, which is crucial in treating conditions like **wet age-related macular degeneration (AMD)** and **diabetic macular edema**. *Interleukin-6* - **Interleukin-6 (IL-6)** is a **pro-inflammatory cytokine** involved in various autoimmune and inflammatory diseases. - Monoclonal antibodies targeting IL-6, such as **tocilizumab**, are used in conditions like **rheumatoid arthritis** and **cytokine release syndrome**, not for ocular neovascularization. *Cluster of Differentiation 20* - **Cluster of Differentiation 20 (CD20)** is a protein found on the surface of **B lymphocytes**. - Monoclonal antibodies against CD20, like **rituximab**, are used in the treatment of **B-cell lymphomas**, **leukemia**, and certain **autoimmune diseases**, not for conditions requiring anti-VEGF therapy. *Epidermal Growth Factor Receptor* - The **epidermal growth factor receptor (EGFR)** is a **tyrosine kinase receptor** involved in cell growth and proliferation. - Monoclonal antibodies targeting EGFR, such as **cetuximab** and **panitumumab**, are used in the treatment of various **cancers**, particularly **colorectal cancer** and **head and neck cancer**.

Q: What is the mechanism of action of Abatacept?

Inhibitor of co-stimulation of T cells. ***Inhibitor of co-stimulation of T cells*** - Abatacept is a **fusion protein** that blocks the **CD28-CD80/86 co-stimulatory pathway**, which is crucial for full T-cell activation. - By binding to **CD80** and **CD86** on antigen-presenting cells, it prevents their interaction with **CD28** on T cells, thus inhibiting T-cell proliferation and cytokine production. *Tumor necrosis factor (TNF) alpha inhibitor* - TNF alpha inhibitors (e.g., **adalimumab**, **infliximab**, **etanercept**) bind to and neutralize **TNF alpha**, a pro-inflammatory cytokine. - While used in similar conditions, their mechanism is distinct from Abatacept's T-cell co-stimulation blockade. *Monoclonal antibody against interleukin-6 (IL-6) receptor* - Drugs like **tocilizumab** target the **IL-6 receptor**, blocking the signaling of **IL-6**, another important inflammatory cytokine. - This mechanism primarily affects cytokine signaling rather than directly inhibiting T-cell activation in the same way as abatacept. *Interleukin-1 (IL-1) receptor antagonist* - **Anakinra** is an example of an **IL-1 receptor antagonist**, which competes with IL-1 for binding to its receptor, thereby blocking its pro-inflammatory effects. - This mechanism focuses on inhibiting the action of IL-1, unlike Abatacept's role in T-cell activation.

Q: Which of the following is NOT typically produced by local anesthetics?

Dysphoria. Detailed Analysis: ***Dysphoria*** - While local anesthetics can cause a range of central nervous system effects with toxicity, **dysphoria** (a state of unease or generalized dissatisfaction with life) is not a typical or primary direct effect of their action on receptors. High doses or systemic absorption might lead to anxiety and restlessness, but dysphoria specifically is uncommon. - The primary mechanism of local anesthetics involves blocking **voltage-gated sodium channels** [1], leading to a reversible loss of sensation, not directly causing mood disturbances like dysphoria. *Euphoria* - **Euphoria** can sometimes be observed with systemic local anesthetic toxicity due to initial CNS stimulation before depression. Some individuals report a transient feeling of well-being or altered mental status with high systemic levels of certain local anesthetics. - This effect is not a direct therapeutic goal but rather an **adverse reaction** associated with systemic absorption and CNS excitation. *Analgesia* - **Analgesia** is the primary therapeutic effect of local anesthetics, achieved by blocking nerve impulse transmission. This prevents the sensation of pain from reaching the brain [1]. - They work by **blocking sodium channels** in nerve membranes [1], thereby inhibiting the initiation and propagation of action potentials [2]. *Muscle relaxation* - **Muscle relaxation** in the area of blockade is a direct consequence of the local anesthetic's action on the motor nerves supplying the muscles. - By blocking nerve conduction in **motor nerve fibers** [1], local anesthetics prevent muscle contraction, leading to temporary skeletal muscle paralysis.

Q: Which of the following is NOT a function of Prostaglandin E1 (PGE1)?

Plays a role in initiating puberty. ***Plays a role in initiating puberty*** - **Prostaglandin E1 (PGE1)** is primarily involved in smooth muscle relaxation, vasodilation, and inflammation, and does not have a direct role in initiating **puberty**. - The initiation of puberty is mainly controlled by the **hypothalamic-pituitary-gonadal (HPG) axis** and surge of **gonadotropin-releasing hormone (GnRH)**. *Used in the management of erectile dysfunction* - **PGE1 formulations** (alprostadil) are used as a topical or intracavernosal injection to treat **erectile dysfunction** by inducing vasodilation in the penis. - Its vasodilatory effects increase blood flow to the corpora cavernosa, leading to **penile erection**. *Modulates inflammatory responses* - **PGE1** is involved in **inflammatory processes**, often exerting both pro- and anti-inflammatory effects depending on the context and specific receptors activated. - It can help to **reduce inflammation** and pain, as well as influencing immune cell function. *Maintains the patency of the ductus arteriosus* - In newborns with **congenital heart defects**, **PGE1** is administered to maintain the **patency of the ductus arteriosus**, allowing for blood flow between the aorta and pulmonary artery. - This is crucial for conditions where pulmonary or systemic blood flow is dependent on a patent ductus, bridging the infant to surgery or other interventions.

Q: Pyridoxine is used in treatment of ?

Homocystinuria. ***Homocystinuria*** - **Pyridoxine (vitamin B6)** is a cofactor for the enzyme **cystathionine beta-synthase**, which is deficient in many forms of homocystinuria. - In pyridoxine-responsive homocystinuria, high doses of pyridoxine can help reduce **homocysteine levels** by stimulating residual enzyme activity. *Galactosemia* - This is an inherited disorder affecting the body's ability to metabolize **galactose**, due to deficiency of enzymes like galactose-1-phosphate uridyltransferase. - Treatment primarily involves dietary restriction of **galactose** and lactose, not pyridoxine. *Phenylketonuria* - This metabolic disorder results from a deficiency in **phenylalanine hydroxylase**, leading to a buildup of phenylalanine. - Treatment involves a strict **low-phenylalanine diet** and sometimes sapropterin (BH4). *Propionic acidemia* - This organic acidemia is caused by a deficiency in **propionyl-CoA carboxylase**, an enzyme requiring **biotin** as a cofactor. - Treatment involves dietary protein restriction and often carnitine supplementation, with **biotin** sometimes used, but not pyridoxine.

Question 1

What is the classification of Lorcaserin?

Accepted Answer

Anti-obesity

Answer

Anti-anxiety

Answer

Anti-smoking

Answer

Anti-helminthic

Question 2

Which of the following pairs are considered physiological antagonists in pharmacology?

Accepted Answer

Histamine and Adrenaline

Answer

Adrenaline and Isoprenaline

Answer

Isoprenaline and Propranolol

Answer

All of the options

Question 3

The mechanism by which ergometrine stops postpartum hemorrhage is that it:

Accepted Answer

Increases tone of uterine muscle

Answer

Induces platelet aggregation

Answer

Promotes coagulation

Answer

Causes vasoconstriction of uterine arteries

Question 4

In ophthalmology, if a patient is allergic to aminoesters, which local anesthetic can be safely used?

Accepted Answer

Prilocaine

Answer

Procaine

Answer

Cocaine

Answer

Tetracaine

Question 5

Which drug is used in the treatment of Type I tyrosinemia?

Accepted Answer

Nitisinone

Answer

Pemoline

Answer

Alogliptin

Answer

Milrinone

Question 6

Ranibizumab is a monoclonal antibody against?

Accepted Answer

VEGF

Answer

Interleukin-6

Answer

Cluster of Differentiation 20

Answer

Epidermal Growth Factor Receptor

Question 7

What is the mechanism of action of Abatacept?

Accepted Answer

Inhibitor of co-stimulation of T cells

Answer

Tumor necrosis factor (TNF) alpha inhibitor

Answer

Monoclonal antibody against interleukin-6 (IL-6) receptor

Answer

Interleukin-1 (IL-1) receptor antagonist

Question 8

Which of the following is NOT typically produced by local anesthetics?

Accepted Answer

Dysphoria

Answer

Muscle relaxation

Answer

Euphoria

Answer

Analgesia

Question 9

Which of the following is NOT a function of Prostaglandin E1 (PGE1)?

Accepted Answer

Plays a role in initiating puberty

Answer

Modulates inflammatory responses

Answer

Used in the management of erectile dysfunction

Answer

Maintains the patency of the ductus arteriosus

Question 10

Pyridoxine is used in treatment of ?

Accepted Answer

Homocystinuria

Answer

Galactosemia

Answer

Phenylketonuria

Answer

Propionic acidemia

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?